JP2019505502A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505502A5
JP2019505502A5 JP2018533169A JP2018533169A JP2019505502A5 JP 2019505502 A5 JP2019505502 A5 JP 2019505502A5 JP 2018533169 A JP2018533169 A JP 2018533169A JP 2018533169 A JP2018533169 A JP 2018533169A JP 2019505502 A5 JP2019505502 A5 JP 2019505502A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen
alkyl
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018533169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505502A (ja
JP6938510B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/068569 external-priority patent/WO2017112951A1/en
Publication of JP2019505502A publication Critical patent/JP2019505502A/ja
Publication of JP2019505502A5 publication Critical patent/JP2019505502A5/ja
Priority to JP2021140812A priority Critical patent/JP7297827B2/ja
Application granted granted Critical
Publication of JP6938510B2 publication Critical patent/JP6938510B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018533169A 2015-12-24 2016-12-23 Ｃｆｔｒ制御因子及びこの使用方法 Active JP6938510B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021140812A JP7297827B2 (ja) 2015-12-24 2021-08-31 Ｃｆｔｒ制御因子及びこの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387590P 2015-12-24 2015-12-24
US62/387,590 2015-12-24
PCT/US2016/068569 WO2017112951A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021140812A Division JP7297827B2 (ja) 2015-12-24 2021-08-31 Ｃｆｔｒ制御因子及びこの使用方法

Publications (3)

Publication Number Publication Date
JP2019505502A JP2019505502A (ja) 2019-02-28
JP2019505502A5 true JP2019505502A5 (OSRAM) 2020-02-06
JP6938510B2 JP6938510B2 (ja) 2021-09-22

Family

ID=59091271

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533169A Active JP6938510B2 (ja) 2015-12-24 2016-12-23 Ｃｆｔｒ制御因子及びこの使用方法
JP2021140812A Active JP7297827B2 (ja) 2015-12-24 2021-08-31 Ｃｆｔｒ制御因子及びこの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021140812A Active JP7297827B2 (ja) 2015-12-24 2021-08-31 Ｃｆｔｒ制御因子及びこの使用方法

Country Status (18)

Country Link
US (6) US10604492B2 (OSRAM)
EP (2) EP4019501B1 (OSRAM)
JP (2) JP6938510B2 (OSRAM)
KR (1) KR102733897B1 (OSRAM)
CN (2) CN108848668B (OSRAM)
AU (1) AU2016379444B2 (OSRAM)
BR (1) BR112018012949B1 (OSRAM)
CL (1) CL2018001715A1 (OSRAM)
CO (1) CO2018007237A2 (OSRAM)
DK (1) DK3394040T3 (OSRAM)
ES (2) ES3066112T3 (OSRAM)
IL (1) IL260208B2 (OSRAM)
MX (2) MX383072B (OSRAM)
PL (1) PL3394040T3 (OSRAM)
PT (1) PT3394040T (OSRAM)
RU (1) RU2749834C2 (OSRAM)
WO (1) WO2017112951A1 (OSRAM)
ZA (1) ZA201804230B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3066112T3 (en) * 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
EP3672598A4 (en) * 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物
IL300628A (en) 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
WO2025179141A1 (en) 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK35124C (da) 1924-03-19 1925-10-12 Niels Christian Carl S Nielsen Anordning ved Ægisolatorer og lignende.
DK72517C (da) 1948-04-08 1951-05-15 Hans Dr Ing Wolf Kobling til paralleldrift af vekselstrømsmotorer.
DK101373C (da) 1962-03-16 1965-03-29 Hoechst Ag Fremgangsmåde til fremstilling af vandopløselige monoazofarvestoffer.
ZA794209B (en) 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62126178A (ja) * 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1994011355A1 (fr) 1992-11-19 1994-05-26 Dainippon Pharmaceutical Co., Ltd. Derive de 3,4-dihydro-1(2-hydroxyphenyl)-2(1h)-quinoxalinone et compose associe
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6403598B1 (en) 1998-01-30 2002-06-11 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
ATE449764T1 (de) * 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
US7163943B2 (en) * 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
NZ532349A (en) 2001-09-21 2007-02-23 Reddy Us Therapeutics Inc Methods and compositions of novel triazine compounds
AU2003272740A1 (en) * 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US20070161637A1 (en) * 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7335770B2 (en) * 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
JP2008538107A (ja) * 2005-03-18 2008-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
WO2008006050A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
PL2149560T3 (pl) 2007-05-22 2015-10-30 Astellas Pharma Inc 1-podstawiony związek tetrahydroizochinolinowy
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2231624A4 (en) * 2007-12-21 2011-07-06 Progenics Pharm Inc TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
AU2009221327B2 (en) 2008-03-05 2014-03-27 Merck Patent Gmbh Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
KR101727762B1 (ko) * 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
CN105130948A (zh) * 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
JP6425724B2 (ja) 2013-08-08 2018-11-21 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10354851B2 (en) 2015-09-11 2019-07-16 Iontof Technologies Gmbh Secondary ion mass spectrometer and secondary ion mass spectrometric method
RU2730855C2 (ru) 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
ES2901002T3 (es) 2015-12-24 2022-03-21 Univ California Derivados de N-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-bencenoacetamida y compuestos relacionados como activadores de CFTR para tratar estreñimiento o colestasis
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
MY195904A (en) 2015-12-24 2023-02-27 Respivert Ltd Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
JP7256631B2 (ja) 2018-11-01 2023-04-12 株式会社豊田中央研究所 距離測定装置

Similar Documents

Publication Publication Date Title
JP2018538354A5 (OSRAM)
RU2018126958A (ru) Кфтр регуляторы и способы их применения
RU2018126959A (ru) Кфтр регуляторы и способы их применения
RU2019105534A (ru) Модуляторы хемокинового рецептора и их применение
PH12019501098A1 (en) Pyrrolopyrimidines as cftr potentiators
JP2024530952A5 (OSRAM)
JP2020514334A5 (OSRAM)
JP2021105002A5 (OSRAM)
JP2012532112A5 (OSRAM)
JP2013530179A5 (OSRAM)
JP2003531103A5 (OSRAM)
JP2010511626A5 (OSRAM)
JP2020535165A5 (OSRAM)
JP2018517760A5 (OSRAM)
JP2018529650A5 (OSRAM)
JP2024517016A5 (OSRAM)
JP2017500334A5 (OSRAM)
JP2014015465A5 (OSRAM)
JP2014525427A5 (OSRAM)
JP2020510054A5 (OSRAM)
ES2293530T3 (es) Derivados de sulfonamidas para el tratamiento de enfermedades.
JP2021535174A5 (OSRAM)
JP2018534286A5 (OSRAM)
JP2019530674A5 (OSRAM)
JP2019507793A5 (OSRAM)